Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Published:2020-05 Issue:5 Volume:7 Page:e370-e380
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Mateos Maria-Victoria,Nahi Hareth,Legiec Wojciech,Grosicki Sebastian,Vorobyev Vladimir,Spicka Ivan,Hungria Vania,Korenkova Sibirina,Bahlis Nizar,Flogegard Max,Bladé Joan,Moreau Philippe,Kaiser Martin,Iida Shinsuke,Laubach Jacob,Magen Hila,Cavo Michele,Hulin Cyrille,White Darrell,De Stefano Valerio,Clemens Pamela L,Masterson Tara,Lantz Kristen,O'Rourke Lisa,Heuck Christoph,Qin Xiang,Parasrampuria Dolly A,Yuan Zhilong,Xu Steven,Qi Ming,Usmani Saad Z

Publisher

Elsevier BV

Subject

Hematology

Reference22 articles.

1. Targeting CD38 with daratumumab monotherapy in multiple myeloma;Lokhorst;N Engl J Med,2015

2. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma;Usmani;Blood,2016

3. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial;Lonial;Lancet,2016

4. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma;Dimopoulos;N Engl J Med,2016

5. Daratumumab, bortezomib, and dexamethasone for multiple myeloma;Palumbo;N Engl J Med,2016

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe;Patient Preference and Adherence;2024-09

2. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

3. Designing a Patient Preference Study on Subcutaneous Medical Devices: Incorporating Health Authority Scientific Advice and Patient Perspectives;2024-08-17

4. Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series;Transplant International;2024-08-01

5. Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries;Journal of Health Economics and Outcomes Research;2024-07-18